Cardiac Arrhythmias in Greenland

NCT ID: NCT05200676

Last Updated: 2024-03-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-16

Study Completion Date

2024-03-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is a phd-study comprising several substudies focusing on cardiac arrhythmias, mainly atrial fibrillation, among Greenlanders in Greenland.

Some previous studies have indicated that the prevalence may be lower than among Westerners, however; studies have also indicated that atrial fibrillation is underdiagnosed.

These studies aim to:

* Estimate the prevalence of AF among Greenlanders in Greenland aged 55 years or older.
* Estimate the prevalence of well-known risk factors among those found to have AF
* Explore the symptoms of those affected by AF in Greenland
* Among part of the participants: estimate the prevalence of autonomic neuropathy as this may cause arrhythmias.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Atrial fibrillation (AF) is the most common cardiac arrhythmia globally and a major risk factor for ischemic strokes, transient ischemic attacks, increased morbidity and mortality.

Risk factors for AF include diabetes, hyperthyroidism, hypertension, obesity, ischemic heart disease (IHD), age and gender with men generally having a higher risk of developing AF.

The current prevalence of cardiac arrhythmias in Greenland is unknown. From 1962 to 1964 12-lead electrocardiograms (ECGs) were performed on 181 adults and only one of these showed AF. A more recent study from 2013 estimating the incidence of ischemic strokes among Greenlanders found that five percent of this study-population had been diagnosed with AF before the incident, while 32.4 % were diagnosed after the incident, suggesting that AF may be underdiagnosed. Comparing the age of the patients to data from Denmark, the authors found that the incidence rate for stroke was higher among almost all younger age groups in Greenland.

Previous studies have shown that ethnicity may influence the risk of developing AF. The genetic profile of the Greenlandic Inuit has already been shown to have a major impact on the risk of developing type 2 diabetes.

Regarding other AF-related risk factors, hypertension is common with a prevalence of app. 40% among men and 32% among women based on self-reported data, and a study comparing data from ECGs performed in 1963 with more current data has shown a rise in the incidence of IHD.

Furthermore, the number of obese people in Greenland is steadily rising and between 1963 and 2008, the proportion of obese people (BMI≥30) increased from 4.0% to 33.2% for men and 8.3% to 24.5% for women between 50 to 69 years.

In conclusion, the risk factors for cardiac arrhythmias are increasing in Greenland and the overall aim of this study is to estimate the prevalence, risk factors, mortality, morbidity and treatment of arrhythmias in Greenland.

Relevance: as mentioned above, this study aims to estimate the prevalence, risk factors, mortality, morbidity and treatment of arrhythmias in Greenland, all of which is currently unknown. By doing this, the study aims to not only improve the treatment rate of arrhythmias, but also lower the prevalence of diseases such as strokes, which are often caused by arrhythmias. By lowering this prevalence, some deaths and cases of disability can be prevented. Furthermore, the investigators hope to assess whether arrhythmias are influenced differently by ethnicity and risk factors such as diabetes in Greenland than in Europe and if patients with certain diseases and/or symptoms have a higher risk of developing arrhythmias and should be monitored more closely.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Arrhythmia Autonomic Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Main group

All included in the study will offered to participate in:

* ePatch-monitoring
* Blood pressure measurement
* Cardial vagal tone
* Questionnaire-assessment

ePatch

Intervention Type DEVICE

ePatch registers the heart rate continuously when attached to the chest of the participant.

Subgroup

Part of the study-population will be offered to participate in en examination with a SmartPill. The Smartpill measures pressure, pH, temperature and movement in the gut. These measurements gives an indication of the function of the autonomic nervous system (ANS) of the participant. Although measured in the gut, this is relevant as ANS-dysfunction may cause arrhythmias.

Only a subgroup of the study population will be offered to participate due to the cost of this examination.

ePatch

Intervention Type DEVICE

ePatch registers the heart rate continuously when attached to the chest of the participant.

SmartPill

Intervention Type DEVICE

SmartPill is swallowed and passes through the digestive system while sending information to a recording device. The pill is passed in the stool and not reused.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ePatch

ePatch registers the heart rate continuously when attached to the chest of the participant.

Intervention Type DEVICE

SmartPill

SmartPill is swallowed and passes through the digestive system while sending information to a recording device. The pill is passed in the stool and not reused.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 50 years old
* Greenlandic ethnicity based on parents' birth place.
* No history of cardiac disease or arrhythmia

Exclusion Criteria

* Celiac disease (for the SmartPill-study)
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aalborg University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nadja Albertsen

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nadja Albertsen, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Aalborg University / University of Greenland and Aalborg University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ilisimatusarfik

Nuuk, , Greenland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Greenland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KVUG 2020-18

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Arrhythmia Cohort Study
NCT07123896 NOT_YET_RECRUITING